The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication - 15/02/21
Abstract |
Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets. The features of the malignant cell in mycosis fungoides and Sézary syndrome are now significantly better understood, including the T helper 2 cell phenotype, regulatory T cell cytokine production, immune checkpoint molecule expression, chemokine receptors, and interactions with the microenvironment. The updated model of CTCL immunopathogenesis provides understanding into clinical progression and therapeutic response.
Le texte complet de cet article est disponible en PDF.Key words : CTCL, cutaneous T cell lymphoma, dermatologic oncology, drug response, immune deficiency, immunopathogenesis, immunotherapy, mycosis fungoides, Sézary syndrome
Plan
Mr Durgin and Mr Weiner contributed equally to this article. |
|
Funding sources: Mr Durgin is supported by National Center for Advancing Translational Sciences grant number TL1TR001880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
Disclosure: Drs Wysocka and Rook are inventors on a pending patent for the use of resiquimod for cutaneous T cell lymphoma. |
|
IRB approval status: Not applicable. |
|
Date of release: March 2021. |
|
Expiration date: March 2024. |
Vol 84 - N° 3
P. 587-595 - mars 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?